139 related articles for article (PubMed ID: 35546288)
1. Immunohistochemical expression of Axin-2, as an implication of the role of stem cell in scar pathogenesis and prognosis.
Bazid HAS; Samaka RM; Mousa MEA; Seleit I
J Cosmet Dermatol; 2022 Nov; 21(11):6010-6020. PubMed ID: 35546288
[TBL] [Abstract][Full Text] [Related]
2. Krox20 expression in abnormal scars: An immunohistochemical study.
Bakry OA; Samaka RM; Fayez N; Seleit I
J Cosmet Dermatol; 2022 Oct; 21(10):5116-5126. PubMed ID: 35416391
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical Evaluation of Leptin Expression in Wound Healing: A Clue to Exuberant Scar Formation.
Seleit I; Bakry OA; Samaka RM; Tawfik AS
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):296-306. PubMed ID: 26258753
[TBL] [Abstract][Full Text] [Related]
4. Hypertrophic and keloid scars fail to progress from the CD34
Limandjaja GC; Belien JM; Scheper RJ; Niessen FB; Gibbs S
Br J Dermatol; 2020 Apr; 182(4):974-986. PubMed ID: 31206605
[TBL] [Abstract][Full Text] [Related]
5. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis - Keloids and hypertrophic scars may be vascular disorders.
Ogawa R; Akaishi S
Med Hypotheses; 2016 Nov; 96():51-60. PubMed ID: 27959277
[TBL] [Abstract][Full Text] [Related]
6. Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars.
Bock O; Yu H; Zitron S; Bayat A; Ferguson MW; Mrowietz U
Acta Derm Venereol; 2005; 85(3):216-20. PubMed ID: 16040405
[TBL] [Abstract][Full Text] [Related]
7. Increased epidermal thickness and abnormal epidermal differentiation in keloid scars.
Limandjaja GC; van den Broek LJ; Waaijman T; van Veen HA; Everts V; Monstrey S; Scheper RJ; Niessen FB; Gibbs S
Br J Dermatol; 2017 Jan; 176(1):116-126. PubMed ID: 27377288
[TBL] [Abstract][Full Text] [Related]
8. Wnt Signaling Pathway Proteins in Scar, Hypertrophic Scar, and Keloid: Evidence for a Continuum?
Chaudet KM; Goyal A; Veprauskas KR; Nazarian RM
Am J Dermatopathol; 2020 Nov; 42(11):842-847. PubMed ID: 32310858
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-mesenchymal transition in the formation of hypertrophic scars and keloids.
Yuan FL; Sun ZL; Feng Y; Liu SY; Du Y; Yu S; Yang ML; Lv GZ
J Cell Physiol; 2019 Dec; 234(12):21662-21669. PubMed ID: 31106425
[TBL] [Abstract][Full Text] [Related]
10. [Hyperplastic scars and keloids. Part I: basics and prevention].
Baisch A; Riedel F
HNO; 2006 Nov; 54(11):893-904; quiz 905. PubMed ID: 17041777
[TBL] [Abstract][Full Text] [Related]
11. Vascularization pattern in hypertrophic scars and keloids: a stereological analysis.
Amadeu T; Braune A; Mandarim-de-Lacerda C; Porto LC; Desmoulière A; Costa A
Pathol Res Pract; 2003; 199(7):469-73. PubMed ID: 14521263
[TBL] [Abstract][Full Text] [Related]
12. Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis.
Ogawa R
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28287424
[TBL] [Abstract][Full Text] [Related]
13. The Role of Hippo Signaling Pathway and ILK in the Pathophysiology of Human Hypertrophic Scars and Keloids: An Immunohistochemical Investigation.
Petrou IG; Nikou S; Madduri S; Nifora M; Bravou V; Kalbermatten DF
Cells; 2022 Oct; 11(21):. PubMed ID: 36359821
[TBL] [Abstract][Full Text] [Related]
14. Keloids and hypertrophic scars: are they two different sides of the same coin?
Köse O; Waseem A
Dermatol Surg; 2008 Mar; 34(3):336-46. PubMed ID: 18177398
[TBL] [Abstract][Full Text] [Related]
15. Characterization of In Vitro Reconstructed Human Normotrophic, Hypertrophic, and Keloid Scar Models.
Limandjaja GC; van den Broek LJ; Breetveld M; Waaijman T; Monstrey S; de Boer EM; Scheper RJ; Niessen FB; Gibbs S
Tissue Eng Part C Methods; 2018 Apr; 24(4):242-253. PubMed ID: 29490604
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase-2 and -9 activities in human keloids, hypertrophic and atrophic scars: a pilot study.
Tanriverdi-Akhisaroglu S; Menderes A; Oktay G
Cell Biochem Funct; 2009 Mar; 27(2):81-7. PubMed ID: 19165813
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical evaluation of COX-1 and COX-2 expression in keloid and hypertrophic scar.
Abdou AG; Maraee AH; Saif HF
Am J Dermatopathol; 2014 Apr; 36(4):311-7. PubMed ID: 24061401
[TBL] [Abstract][Full Text] [Related]
18. [Detection of apoptosis by in situ labeling and study on the expression of PCNA in hypertrophic scars and keloids].
Zhao BC; Qian L
Hunan Yi Ke Da Xue Xue Bao; 2000 Feb; 25(1):73-6. PubMed ID: 12212258
[TBL] [Abstract][Full Text] [Related]
19. Keloids and Hypertrophic Scars: Pathophysiology, Classification, and Treatment.
Berman B; Maderal A; Raphael B
Dermatol Surg; 2017 Jan; 43 Suppl 1():S3-S18. PubMed ID: 27347634
[TBL] [Abstract][Full Text] [Related]
20. The effect of the anti-allergic agent avil on abnormal scar fibroblasts.
Venugopal J; Ramakrishnan M; Habibullah CM; Babu M
Burns; 1999 May; 25(3):223-8. PubMed ID: 10323606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
